Myeloid growth factors, such as granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor, have been used to decrease the duration of chemotherapy-induced neutropenia and thereby reduce the incidence and severity of infections in various regimens used to treat acute myeloid leukemia and acute lymphoblastic leukemia. These growth factors have also been used to recruit dormant myeloid leukemia cells into the S phase of cell cycle in order to increase their susceptibility to the antileukemic effects of agents such as cytarabine. Multiple prospective randomized trials have examined the benefit and safety of the addition of growth factors before, during, and after chemotherapy. A reduction in the duration of neutropenia has been the most consistent finding; this has not been associated with stimulation of leukemia cells, the main concern of using this strategy. Unfortunately, few studies have reported a benefit in prolonging the duration of disease-free survival or overall survival. Other cytokines, including interleukins and thrombopoietin, have also been evaluated for their theoretical ability to recruit immune mechanisms to eradicate residual leukemia burden after chemotherapy, and to stimulate platelet production. In this review, we summarize the clinical experience with these growth factors in treating acute leukemias.
Myeloid colony-stimulating factors

Acute myeloid leukemia
Myeloid colony-stimulating factors, including granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF), have been evaluated as adjuncts in the treatment of patients with acute myeloid leukemia (AML). [1] [2] [3] [4] A number of clinical trials have examined whether these agents can shorten the duration of chemotherapyinduced neutropenia and reduce the incidence of infections (Table 1) . Other studies have evaluated the efficacy of these agents to enhance the antileukemic effects of chemotherapy by recruiting dormant leukemia cells into a sensitive phase of cell cycle (Table 2 ). This strategy has been based on the premise that clonogenic leukemic cells are quiescent, and as a result, resistant to the effects of standard chemotherapeutic agents. As such, the use of growth factors may activate these cells and thereby promote their responsiveness to chemotherapy. 5 In vitro studies have demonstrated that the simultaneous exposure of leukemic cells to cell-cycle-specific drugs such as cytarabine and cytokines enhances the cytotoxic effects of the former. [6] [7] [8] [9] [10] Furthermore, the concomitant exposure of leukemic cells to cytarabine and growth factors results in an increased level of the active cytarabine-triphosphate (Ara-CTP) and increased DNA uptake of radiolabeled cytarabine. 11 Use of growth factors after chemotherapy. A significant concern in the use of CSFs during AML induction therapy was the stimulation of residual normal precursors in the marrow, leading to increased susceptibility to chemotherapy and consequent prolonged cytopenia. A further concern was the potential stimulation of leukemic cell growth. However, the safety of administration of growth factors before, during, and after induction chemotherapy has now been borne out by the results of small exploratory studies as well as large randomized trials (Tables 1 and 2 ).
The most consistent finding in trials where either G-or GM-CSF is administered after completion of chemotherapy has been acceleration of neutrophil recovery by approximately 2-7 days. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Owing to the lack of comparative trials, there are no indications that one cytokine may be superior to the other in this regard. Similarly, the theoretical concern of an adverse effect on platelet recovery does not appear to be relevant. However, this strategy has not become the standard of care as it is not clear that such acceleration of neutrophil recovery is clinically meaningful. 3 Such limited shortening of the duration of neutropenia has not been accompanied by a reduction in the incidence of documented, severe and fatal infections. 12, 15, 20 Furthermore, in the majority of these studies, the complete remission (CR) rate, 12, [15] [16] [17] [18] [19] disease-free survival (DFS), [15] [16] [17] [18] 20 and overall survival (OS) 12, [14] [15] [16] [17] [18] are not affected by growth factor therapy. Some of these studies have demonstrated an increase in the CR rate, 13, 14 and even the OS, when using growth factor therapy. 13 However, it is likely that confounding issues contribute to these differences. 3 In the study by Rowe et al.,
13 a higher rate of severe infections and a shorter median survival than expected in the placebo group were potential contributing factors to the differences in the OS. However, it is also important to consider that the majority of these studies report their data on an intent-to-treat basis and it is possible that the beneficial clinical effects of these cytokines may be underestimated owing to their early discontinuation as a result of real or perceived toxicity. This is particularly important in patients at the highest risk of infection-related mortality.
Uncontrolled 22 as well as prospective randomized trials 20 have investigated the benefit of administering growth factors after intensive consolidation chemotherapy in patients who have achieved CR. In the study by Harousseau et al., 20 194 patients in CR after induction therapy were randomized to receive G-CSF (100 patients), or no G-CSF (94 patients) after two courses of intensive consolidation chemotherapy. The median duration of neutropenia, the median duration of hospitalization and the median duration of antifungal therapy were reduced for the G-CSF group, whereas the incidence of microbiologically documented infections, the toxic death rate, the 2-year DFS and the 2-year OS were not affected by G-CSF administration. 20 Considerable variation of the chemotherapy agents and their dose/schedule used in these trials limits the ability to discern their potential effect on the outcome independent of the growth factor therapy (Table 3) . However, a similar reduction in the duration of neutropenia by several days suggests that the effect of the cytokines is independent of the regimen or schedule. For example, in a study by the Australian Leukemia Study Group (ALSG), glycosylated G-CSF was administered after the completion of high-dose cytarabine-containing chemotherapy, and a reduction in the duration of neutropenia of 4 days (P ¼ 0.0005) in patients who received the cytokine was reported. 17 This is of a similar magnitude to other studies employing standard-dose cytarabine. [12] [13] [14] [15] [16] 21, 23 Other problems with the direct comparison of these studies include the frequency of monitoring of the blood counts in the different studies, different age ranges of the study populations (Table 1) , lack of uniformity in time of initiation and duration of growth factor support, differing outcome of the placebo groups, Abbreviations: CSF, colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; G-CSF: granulocyte colony-stimulating factor; A, after chemotherapy; B, before chemotherapy; D, during chemotherapy. *Recovery to 500/ml and 1000/ml, respectively. 
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X61 G-CSF D, A Improved CR, no survival benefit o80
Abbreviations: CSF, colony stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; G-CSF, granulocyte colony-stimulating factor; B, before chemotherapy; D, during chemotherapy; A, after chemotherapy; DFS, disease-free survival; OS, overall survival. *Studies in relapsed/refractory patients.
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F Ravandi and diversity of decision-making process regarding antibiotic therapy and hospitalization. 3 Despite these differences, the majority of these trials conclude that growth factors can be safely administered after chemotherapy to patients with AML and they accelerate the recovery of neutrophils. 19, 20, 24 Any disadvantage in their use would relate to the economics of such a strategy and whether the benefits justify the significant cost that may be associated with such a universal approach.
Several randomized studies have reported a beneficial effect on the duration of fever, parenteral antibiotic use, and hospitalization (Table 1) suggesting that the use of growth factors is of economical benefit. 15, 17, 18, 20 An analysis of the study from Southwest Oncology Group (SWOG) did not demonstrate a reduction in the overall cost of supportive care despite the beneficial effect of G-CSF on the duration of neutropenia and infections. 15, 25 However, according to a report from the study by the Eastern Co-operative Oncology Group (ECOG), the use of GM-CSF was associated with cost savings in addition to a survival benefit and a reduction in duration of neutropenia and severity of infections. 13, 26 Furthermore, the costs of therapy in the placebo groups in the two trials were significantly different, leading to the suggestion that the cost analysis could be institution-specific. 3 On the basis of the available data, no specific recommendations regarding the use of G-CSF and GM-CSF in postinduction period can be made with certainty. It is reasonable to assume that these agents are safe to administer and can shorten the neutropenic period; it is, however, unclear whether their universal prophylactic administration translates into a clinical benefit. On the basis of the available data, it may be more appropriate to consider initiating these growth factors in subsets of patients who are expected to have a prolonged and/or clinically complicated period of neutropenia, such as elderly or heavily pretreated patients. 3 However, such recommendation is at best based on incomplete data and requires further confirmation.
Concomitant use of growth factors with chemotherapy.
Relapse is the most important cause of treatment failure in AML. This is particularly true for the younger patients who are able to avoid therapy-related mortality. 27 The likely cause of such failure is the minimal residual disease that has escaped the cytotoxic effects of chemotherapy. Primary resistance to chemotherapy, particularly in the elderly patients, accounts for another major cause of treatment failure and may be related to the existence of a small population of quiescent clonogenic blasts, which are resistant to chemotherapy. 5 In vitro and in vivo studies have demonstrated the ability of growth factors to recruit these quiescent cells into a phase of cell cycle where these are more susceptible to the cytotoxic effects of chemotherapy. 11, 28 Exposure of leukemic cells to growth factors and cytarabine increases intracellular ara-CTP and DNA uptake of radiolabeled cytarabine into the leukemic cells. 6, 7, 9 These preclinical studies provided the rationale for a number of trials investigating the safety and efficacy of concomitant administration of colony-stimulating factors with chemotherapy (Table 2) .
This strategy has not been consistently effective and no significant clinical benefit has been reported in the majority Abbreviations: A, cytarabine; D, daunorubicin; E, etoposide; Id, idarubicin; M, mitoxantrone; T, thioguanine, ICC, intensive consolidation chemotherapy; CSF, colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; G-CSF, granulocyte colony-stimulating factor; Am, amsacrine.
Cytokine therapy in acute leukemias F Ravandi of these trials (Table 2 ). In a study by Witz et al. 29 conducted by the Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM), a significant improvement in the 2-year DFS in the patients who received GM-CSF during and after induction chemotherapy as compared to the placebo group (48 versus 21%; P ¼ 0.003) was noted. This was highly significant in the cohort of patients aged 55-64 years , but only marginal in patients X65 years of age. There was a trend toward a longer OS in the GM-CSF group (P ¼ 0.082). The investigators concluded that concomitant administration of GM-CSF with chemotherapy shortened the time to neutrophil recovery and prolonged DFS and OS, particularly in patients 55-64 years. The CR rate was not improved. 29 Lowenberg et al. 30 2 once daily beginning 1 day before start of chemotherapy and continued until the absolute neutrophil count (ANC) was greater than 1.0 Â 10 9 /l. 31 Complete remission was achieved by 64% of patients not receiving GM-CSF and 65% of patients who received the growth factor. Furthermore, the median remission duration and the median OS were not statistically superior in the GM-CSF arm. The median time to neutrophil recovery was 25 versus 17 days (P ¼ 0.03) in favor of GM-CSF-treated arm. Also, fewer positive blood cultures were reported in this group. In another recently published study, 722 patients with newly diagnosed AML were randomized into four treatment arms: (1) no G-CSF (glycosylated); (2) G-CSF during chemotherapy; (3) G-CSF after chemotherapy until recovery of neutrophils or day 28; and (4) G-CSF during and after chemotherapy. 24 The CR rate was 48.9% in group (1), 52.2% in group (2), 48.3% in group (3), and 64.4% in group (4). Complete remission rate was significantly higher in patients who received G-CSF during chemotherapy (58.3% in groups 2 þ 4, versus 48.6% in groups 1 þ 3, P ¼ 0.009). No significant difference was reported for groups 1 þ 2 versus 3 þ 4. Patients who received G-CSF after chemotherapy had a shorter time to neutrophil recovery and a shorter hospitalization (Po0.001 and Po0.001, respectively). 24 However, several trials examining the role of 'priming', using either GM-CSF or G-CSF in newly diagnosed patients have not reported any improvements in CR rate, DFS, or OS.
21,32-35
Similar studies in previously treated patients with relapsed or refractory AML have also failed to demonstrate a significant benefit. 36, 37 However, these studies as well some uncontrolled trials 38, 39 have demonstrated the safety of this approach with no evidence of an adverse effect on the outcome. However, Zittoun et al. 23 reported a significant decrease in the CR rate when GM-CSF was administered after chemotherapy (with or without concomitant therapy during induction). This lower CR rate appeared to be related to increased resistance and persistent leukemia.
Despite the existence of multiple clinical studies evaluating the role of growth factors in priming the leukemic cells, few studies have evaluated the cellular in vitro data, monitoring the attempted recruitment of the target leukemic blasts into the chemotherapy sensitive phase of cell cycle. In the report by Rowe et al., 40 106 patients (including 53 patients receiving GM-CSF and 53 receiving placebo) had correlative samples obtained on days 0 and 2 of the study. The mean change in S phase percentage for placebo patients was 0.25%, and the mean change with GM-CSF was 2.05% (P ¼ 0.003), confirming the intended effect of GM-CSF. However, this increase did not differ between the patients attaining CR and those who did not, suggesting that priming for 48 h with GM-CSF, at the dose and timing of the study, did not have a sufficient effect to translate to clinical benefit. 40 Differences in the design of these trials including the sequence of administration of growth factors, and differences in the chemotherapeutic agents and patient characteristics make comparison of these studies difficult. Additional trials are necessary before the strategy of priming with growth factors could be recommended as standard of care. 3, 5 It may be the case that certain subsets of patients may benefit from such strategy. 41 It may therefore be more appropriate to design studies in specific subgroups of patients. 3 
Acute lymphoblastic leukemia
The success in the treatment of acute lymphoblastic leukemia (ALL) in children and younger adults has largely been attributed to risk-adapted application of intensified regimens for induction and consolidation therapy as well as improvements in supportive care. 42, 43 Adaptation of successful pediatric regimens has led to significant improvements in remission induction for adults. However, the ability to maintain DFS has remained disappointingly low for adults, with only 25-50% of these patients achieving long-term DFS. 43, 44 Further attempts in improving disease outcome are based on a better understanding of the biology of ALL, and improved supportive care.
Infectious complications during the prolonged periods of neutropenia have been a major cause of morbidity and mortality. Several trials have investigated the role of growth factors in accelerating the neutrophil recovery. [45] [46] [47] [48] Prospective, randomized studies in children [49] [50] [51] [52] [53] [54] [55] and adults [56] [57] [58] [59] [60] [61] with ALL have investigated the overall safety and benefit of administration of growth factors together with or after dose-intensive ALL therapy (Tables 4 and 5 ). The administration of growth factors in the majority of these studies reduced the hematological toxicity of dose intensification and led to better compliance with the treatment schedule. Ohno et al. 57 compared three doses of G-CSF (2, 5, and 10 mg/kg per day) and recommended 5 mg/kg per day as the optimal dose. Delorme et al. 62 suggested that the improvement in chemotherapy dose intensity in children with high-risk ALL was not associated with an increase in the cost of therapy. Pui et al. 55 reported that the use of G-CSF in children with ALL was associated with a significantly lower incidence of Cytokine therapy in acute leukemias F Ravandi documented infections, shorter median hospital stays, and fewer delays in starting consolidation chemotherapy. 55 In the study by Larsen et al., 59 there were no detectable differences during the induction course for the neutrophil recovery end points or hospitalization between patients younger or older than 60 years. Platelet recovery was significantly faster for patients X60 years of age, who received G-CSF (17 days versuss 26 days; P ¼ 0.04) In this age group, the CR rate (81 versuss 55%) and induction mortality rate (10 versuss 25%) were in favor of patients who received G-CSF; although these differences were not statistically significant, probably due to the small number of patients. 59 They suggested that the impact of growth factor therapy is likely to be most apparent in the subset of patients who would otherwise have the slowest recovery, including the elderly, the malnourished and those patients who had received other myelosuppressive medication or had ongoing infections. 59 In summary, the use of growth factors accelerates neutrophil recovery, and may allow an increase in chemotherapy dose intensity. In some studies, this has been associated with an improved CR rate and survival.
Other cytokines used in acute leukemias
Interleukin-2
Interleukin-2 (IL-2) has been of limited use in the treatment of hematological malignancies, mainly because of the inability to mount a host-cell-mediated immune response as a result of host-related and chemotherapy-induced immunosuppression. The known ability of IL-2 to recruit T-cells and in particular natural killer (NK) cells, as well as the efficacy of the immune system to eradicate minimal residual leukemia provided the rational for a number of studies of IL-2 in acute leukemias. [63] [64] [65] [66] [67] [68] Clinical responses have been reported, but generally these were only observed in patients with limited disease. 66, 67 Toxicity in the form of fever, hypotension, vascular leak, thrombocytopenia, rash, and sepsis has generally been acceptable, in particular for lower dose regimens. 69 Owing to the higher likelihood of efficacy of such biological therapy in patients with minimal residual disease, IL-2 has also been investigated as maintenance therapy in second or later remission, 70, 71 or after autologous or allogeneic transplantation. [72] [73] [74] [75] [76] [77] On the basis of the efficacy of IL-2 in these trials, it was hypothesized that the use of IL-2 in first CR might be relatively more beneficial. 78 Cortes et al. 78 administered IL-2 4.5 Â 10 5 U/m 2 daily by continuous infusion for 12 weeks, plus boluses of 1 Â 10 6 U/m 2 on day 8 and weekly thereafter to 18 patients with AML in first CR and compared them to historical controls. Although IL-2 administration was feasible and tolerable, no statistically significant improvements in DFS and CR duration was reported. 78 A study by CALGB examined the tolerability of IL-2 after intensive chemotherapy in 35 elderly patients with AML in first CR. 79 Patients received low-dose IL-2 (1 Â 10 6 IU/m 2 /day subcutaneously for 90 days) or low dose IL-2 with intermittent pulse doses (6-12 Â 10 6 IU/m 2 /day subcutaneously for 3 days) every 14 days for a maximum of five pulses. Both regimens were well tolerated with similar toxicity profile including grade 1-2 fatigue, fever, nausea, anemia, injection site reactions, and thrombocytopenia. Grade 3-4 hematological toxicity was uncommon. 79 The median OS for the group was 1.1 years. Similarly, Sievers et al. 41 G-CSF Faster neutrophil recovery, reduced incidence of febrile neutropenia Geissler et al. 58 
53
G-CSF Reduction in duration of neutropenia, reduced incidence of febrile neutropenia and documented infections Larsen et al. 59 
198
G-CSF Reduction of duration of neutropenia and thrombocytopenia and hospitalization, higher CR rate and fewer deaths during induction, no effect on DFS and OS Ifrah et al. 60 
67
GM-CSF Improved incidence of mucositis during induction Holowiecki et al. 61 
64
G-CSF Reduced duration of neutropenia, lower infection rate, faster completion of inductionconsolidation, shorter hospital stay, higher 2-year survival, lower 2-year relapse rate
Abbreviations: CSF, colony-stimulating factor; G-CSF, granulocyte colony-stimulating factor; DFS, disease-free survival; OS, overall survival.
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Pegylated rHuMGDF
Recombinant human megakaryocyte growth and development factor (rHuMGDF) is a potent thrombopoietic agent and has been modified by the addition of a polyethylene glycol moiety to increase its circulating half-life. Randomized, placebocontrolled trials examining the role of pegylated rHuMGDF (PEG-rHuMGDF) in acute leukemia therapy have been reported. 81, 82 Archimbaud et al. 82 randomized 108 adult patients with de novo AML to receive one of two dose schedules of PEGrHuMGDF or placebo. There was no effect on the median time to transfusion-independent platelet recovery (420 Â 10 9 /l). Similarly, there was no apparent effect on the stimulation of leukemia, time to neutrophil recovery or red blood cell transfusion requirements. 82 Schiffer et al. 81 randomized newly diagnosed AML patients to receive either 2.5 or 5 mg/kg/day of PEG-rHuMGDF or a placebo after completion of chemotherapy. A higher platelet count in remission was achieved after cytokine therapy, but there was no improvement in platelet transfusion requirements or CR rate. The drug was tolerated well in both studies. 81, 82 Further development of PEG-rHuMGDF has been hindered by reports of development of cytopenias with neutralizing antibodies to thrombopoietin after its use to support multicycle chemotherapy. 83 
Interleukin-11
Human IL-11 is a multipotential cytokine that is involved in numerous biological activities including hematopoiesis and also displays anti-inflammatory properties. Interleukin-11 has been approved for the treatment of chemotherapy-induced thrombocytopenia. Estey et al. 84 treated 51 patients (X60 years) with AML or advanced MDS with gemtuzumab ozogamicin (GO) with or without IL-11. Addition of IL-11 to GO was associated with an increased CR rate, but no survival benefit was reported. Furthermore, when compared with historical patients treated in the same institution with standard chemotherapy, no benefit could be demonstrated for GO/IL-11-treated patients. 84 Administration of IL-11 has been reported to reduce the incidence of bacteremia in patients with acute leukemias undergoing chemotherapy. 85 In a randomized, double-blind, placebocontrolled study, 40 patients with hematological malignancies (including 21 with AML and 14 with ALL), who were undergoing chemotherapy received either recombinant human IL-11 (rhIL-11) 50 mg/kg or placebo by daily subcutaneous injection from the day before starting chemotherapy until resolution of neutropenia or day 21. 85 Significantly fewer patients receiving the cytokine developed bacteremia than those receiving the placebo (P ¼ 0.02). Time to the first bacteremic event was also longer for the patients who received rhIL-11 than for those who received placebo (P ¼ 0.03). 85 The authors concluded that rhIL-11 reduces the frequency of bacteremia possibly by gastrointestinal cytoprotective or immunological mechanisms.
Other cytokines
A number of other cytokines have been evaluated as adjuncts to the treatment of patients with acute leukemia. Interleukin-3 (IL-3) was evaluated in combination with induction chemotherapy including daunorubicin or mitoxantrone and cytarabine in 20 patients with AML and was reported to be tolerated with acceptable toxicity. 86 More recently, the investigators at the EORTC reported the results of a randomized study of low-dose cytarabine, either alone or in combination with GM-CSF or IL-3 in 180 patients with myelodysplastic syndrome (MDS) including 73 patients with refractory anemia with excess blasts in transformation (RAEBt). 87 There was no statistically significant difference between the three study arms with regards to response rate and degree of cytopenia, and the authors concluded that the combination of low-dose cytarabine and GM-CSF or IL-3 cannot be recommended for routine use in this population. 87 Palifermin is an N-terminal, truncated version of endogenous keratinocyte growth factor with keratinocytestimulating activity. 88 In a randomized study, the effects of palifermin were compared with placebo in 212 patients with hematological cancers undergoing chemotherapy. 89 Palifermin reduced the duration and severity of oral mucositis after intensive chemotherapy and radiotherapy. Its role in the treatment of patients with acute leukemia outside the setting of transplantation remains unclear. Newer agents such as AMG-531, a thrombopoietin receptor ligand are undergoing further evaluation. 90 
Conclusions
Increased understanding of the role of a number of cytokines and chemokines has led to the evaluation of their role as adjuncts in the management of patients with hematological malignancies. A number of clinical trials have examined the role of myeloid colony-stimulating factors in treating patients with acute leukemias and have, in general, suggested a beneficial effect by reduction of duration of neutropenia as well as an improvement in dose intensity of chemotherapy. However, the majority of these studies have not reported a meaningful benefit in increasing the OS or DFS. A recent trial did show an improvement in OS and DFS in patients with standard-risk AML when G-CSF was administered during induction chemotherapy. 30 Overall, however, the exact clinical role of colonystimulating factors in the management of acute leukemias remains undefined.
A number of other cytokines have also been evaluated for their theoretical effects in recruiting the immune system to eradicate minimal residual leukemia. In general, the application of these agents has been limited owing to the difficulties inherent to the biological function and delivery of such pleiotropic agents, where doses needed to achieve the desired immune enhancement are generally associated with significant side effects. Newer cytokines and megakaryocyte-stimulating factors are likely to provide us with more options in treating patients with hematological malignancies recovering from chemotherapy.
